New data from Novel START trial accepted for presentation

Data from Symbicort Turbuhaler Novel START trial among 73 AstraZeneca abstracts accepted for presentation at ATS

New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American Thoracic Society (ATS) 2019 International Conference.

Novel START, an open-label trial designed to reflect real-world practice, assesses the effectiveness of Symbicort Turbuhaler as a potential anti-inflammatory reliever taken as-needed, compared with two of the most commonly used treatment regimens in mild asthma: as-needed short-acting beta2-agonist (SABA) alone or low-dose inhaled corticosteroid (ICS) maintenance treatment plus as-needed SABA.

AstraZeneca will also present new science supporting its biologics portfolio and pipeline. Presentations include: data from an integrated analysis of Fasenra’s (benralizumab) long-term efficacy and safety profile and ability to reduce oral corticosteroid use in patients with severe eosinophilic asthma; the impact of tezepelumab on hospitalisation and emergency department visits; and the first-in-human data for the company’s potential inhaled biologic AZD1402, an IL-4Ra antagonist, currently in development for the treatment of asthma.

Tom Keith-Roach, Senior Vice President, Respiratory, AstraZeneca, said: “We look forward to sharing the results from the Novel START trial which looks at Symbicort used as an anti-inflammatory reliever versus short-acting beta2-agonist, the most commonly used reliever therapy today.

“In biologics, new long-term efficacy and safety data continues to build Fasenra’s clinical profile, and with more than 70 abstracts overall, AstraZeneca is demonstrating its commitment to advancing respiratory science.”